linjc16/ctgov huggingface dataset:
Vocal Demands Among Classroom Teachers

Study Overview
=================
Brief Summary
-----------------
The purpose of the study A comparison of vocal demands with vocal performance among classroom teachers is to gather information about the voice production of teachers using three separate strategies: (a) measures of voice assessed with the Computerized Speech Lab (CSL) and the Phonatory Aerodynamic System (PAS) instruments in the SIUC Voice Lab.

Detailed Description
-----------------
(a) measures of voice assessed with the Computerized Speech Lab (CSL) and the Phonatory Aerodynamic System (PAS) instruments in the SIUC Voice Lab

Official Title
-----------------
A Comparison of Vocal Demands With Vocal Performance Among Classroom Teachers

Conditions
-----------------
Voice Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Enrollment in teaching education programs; active teachers. Exclusion Criteria: Current diagnosed with voice disorder.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental group.<br>Participants are either student teachers or practicing teachers. | |
| Control Group.<br>Participants are no students teachers or practicing teachers. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acoustic measures of voice. | Acoustic measures of voice (i.e., fundamental frequency, total phonation time, and SPL. Participants will be tested three separate times distributed in equal periods throughout one academic semester (i.e., 16 weeks). | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify changes in aerodynamic measures of voice. | Identify changes in aerodynamic measures of voice (airflow). Participants will be tested three separate times distributed in equal periods throughout one academic semester (i.e., 16 weeks). | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Voice, aerodynamics, acoustics
Feasibility Study of Anti-inflammatory Cytokines in Whole Blood in Osteoarthritis Patients

Study Overview
=================
Brief Summary
-----------------
This is a feasibility study to determine if anti-inflammatory cytokines can be concentrated from patients with osteoarthritis.

Official Title
-----------------
A Feasibility Study to Determine the Up-regulation of Anti-inflammatory Cytokines in Whole Blood From Patients With Osteoarthritis

Conditions
-----------------
Osteoarthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: radiographic evidence of osteoarthritis signed informed consent Exclusion Criteria: Pregnancy < 18 years of age blood clotting disorder or active hematologic cancer undergoing chemotherapy history of rheumatoid arthritis septic joint or fracture active infection or history of chronic infection use of cytokine blocking drugs with the last 6 months intra-articular steroid or hyaluronic acid (HA) injection within last 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| osteoarthritis patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure anti-inflammatory cytokines |  | immediately after processing | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
osteoarthritis
Controlled Study of the Use of Quetiapine Fumarate in the Treatment of Patients With Bipolar Depression

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the efficacy of quetiapine compared to placebo in the treatment for a major depressive episode in patients with bipolar disorder after receiving treatment for up to 8 weeks.

Official Title
-----------------
A Confirmatory Multicenter, Double-blind, Randomized, Placebo Controlled Study of the Use of Quetiapine Fumarate (SEROQUEL) in the Treatment of Patients With Bipolar Depression

Conditions
-----------------
Bipolar Disorder

Intervention / Treatment
-----------------
* Drug: Quetiapine Fumarate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Provision of informed consent before enrollment and any study-specific procedures. Patients deemed incapable of providing written consent will not be enrolled in this study; outpatient status Exclusion Criteria: More than 8 mood episodes in the past year from screen (visit 1); A current Axis I disorder other than bipolar disorder within 6 months of screening; patients with clinically significant abnormal laboratory findings in the investigator's judgment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Quetiapine Fumarate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline to week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the incidence of treatment-emergent mania compared to placebo |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bipolar I Disorder
Beta Cell Function in Women With Turner Syndrome

Study Overview
=================
Brief Summary
-----------------
Diabetes is more frequent in women with Turner syndrome. The purpose of this study is to see, in what ways the glucose metabolism is different in this study population. The hypothesis is that women with Turner Syndrome have an impaired insulin production (beta cell function).

Official Title
-----------------
Beta Cell Function in Women With Turner Syndrome

Conditions
-----------------
Turner Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Turner syndrome Exclusion Criteria: Diagnosed diabetes BMI>30 Untreated cardiac or thyroid disease Cancer illness

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to gather stool samples from subjects with inflammatory bowel disease (IBD) to be added to a test set of stool samples that will be utilized to help select molecular markers and determine the optimal sensitivity and specificity values for the Exact IBD-ACRN surveillance test for colorectal cancer (CRC).

Official Title
-----------------
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)

Conditions
-----------------
Inflammatory Bowel Disease, Colorectal Neoplasms, Digestive System Diseases, Colonic Diseases, Colorectal Cancer

Intervention / Treatment
-----------------
* Device: Stool Collection Kit


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female 18 - 84 years of age, inclusive, who have been diagnosed with IBD. Willing to provide a stool sample ≤120 but ≥7 days after a surveillance colonoscopy, which was negative for cancer/dysplasia. Written informed consent document signed and dated by the subject. Exclusion Criteria: Any condition that in the opinion of the investigator should preclude participation in the study. A history of aerodigestive tract cancer. Prior colorectal resection, except ileocolic resection in Crohn's disease patients. IBD limited only to the rectum. Subject has participated in any clinical study within the previous 30 days wherein an investigational compound or device was, or may have been, introduced into the subject.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 84 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| IBD<br>Subjects will be men and women, 18-84 years of age, inclusive, who have been diagnosed with IBD. Each with a screening colonoscopy resulting in normal findings. | Device: Stool Collection Kit<br>* Stool Collection Kit.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity and Specificity of the Exact CRC diagnostic screening test. | The primary endpoint is point estimates of the sensitivity of the diagnostic test for detection of colorectal cancer in IBD patients. | 15 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Inflammatory Bowel Disease, Cancer, Colorectal Cancer, Neoplasm, Colorectal Neoplasm, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Digestive System Diseases, Gastrointestinal Diseases, Colonic Diseases, Intestinal Diseases, Rectal Diseases
Pharmacokinetics of MCS in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
This study is to examine the pharmacokinetics, absorption and serum concentrations of MCS and other components after once-daily oral dosing of MCS.

Detailed Description
-----------------
This study is an open-label, multiple-dose study, whose objective is to examine the pharmacokinetics of MCS and other components after once-daily oral dosing for 21 days. Subjects will undergo a 14-day washout phase and then enter the 21-day treatment phase. During the treatment phase, subjects will receive MCS, once-daily within one hour after the evening meal. After completion of the treatment phase, subjects will enter a post-treatment 42-day washout phase. Throughout each of these phases, blood samples will be collected and assayed for concentrations of MCS and other components. The duration of protocol participation is expected to be 77 days for each eligible subject who completes the study.

Official Title
-----------------
An Open-Label, Multiple-Dose Study of MCS-2 to Examine the Pharmacokinetics of MCS and Other Components After Once-daily Oral Dosing in Healthy Adult Volunteers

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: MCS-2 soft-gel capsule


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal healthy volunteers 18 years of age or older Exclusion Criteria: Subjects who can not comply with the study procedures or sign the informed consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MCS-2<br> | Drug: MCS-2 soft-gel capsule<br>* MCS-2 30 mg/day<br>* Other names: MUS;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum MCS and other components levels |  | 21 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of treatment-emergent adverse events |  | 21 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pharmacokinetics, PK, MCS, Benign Prostatic Hyperplasia, Multi-Carotenoids, Healthy subjects
Clinical Trial of Novel Implantation Promoting Medium (EmbryoGlue) to Improve IVF Success Rates

Study Overview
=================
Brief Summary
-----------------
Hypothesis: a special solution for improving human embryo implantation, when added to the solution during embryo transfer, will improve implantation rates in embryo transfers using previously frozen embryos.

Detailed Description
-----------------
EmbryoGlue (TM) is added to embryo transfer solutions immediately prior to the transfer of frozen-thawed human embryos before placement of embryos into the patient uterus.

Official Title
-----------------
Prospective Randomized Clinical Trial of Novel Implantation Promoting Medium (EmbryoGlue) to Improve IVF Success Rates

Conditions
-----------------
Embryo Implantation, Infertility

Intervention / Treatment
-----------------
* Other: EmbryoGlue


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Frozen embryo transfer patients, men over the age of 18 and women between the ages of 18 and 42 completed years (if using their own eggs and with embryos frozen before 39 completed years) or 18 to 50 completed years if using donated eggs. Exclusion Criteria: Prior participation in this study, blastocyst transfers, single embryo transfer for medical reasons, prior embryo transfer with large amount of blood on the outside of the catheter, > or = 3 consecutive failed embryo transfers at Mayo Clinic (fresh or frozen-thawed cycles).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Other: EmbryoGlue<br>* G2 culture media from Vitrolife which contains hyaluronic acid<br>|
| No Intervention: B<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pregnancy Rate |  | one month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implantation rate |  | two months |
Glaucoma After Congenital Cataract Surgery

Study Overview
=================
Brief Summary
-----------------
To determine the incidence of glaucoma following bilateral congenital cataract removal and estimate the associated risk factors in a large cohort to provide guidance for clinical practice.

Detailed Description
-----------------
A prospective longitudinal cohort study of pediatric patients who underwent surgery for congenital/infantile cataracts between January 2011 and December 2025 was performed.

Official Title
-----------------
Glaucoma After Congenital Cataract Surgery

Conditions
-----------------
Glaucoma, Congenital Cataract

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: a diagnosis of bilateral congenital cataracts, the etiologies include congenital idiopathic cataract and congenital cataract associated with a systemic syndrome or ocular anomalies; cataract surgery performed in ZOC; age at cataract removal younger than 16 years; Exclusion Criteria: the preoperative IOP was above 21 mm Hg; family history of glaucoma; signs of preoperative glaucoma were present, such as corneal clouding, corneal enlargement, excessive cup-disc ratio and myopic shift; ocular trauma history; previous surgery intervention and they were noncompliant with our follow-up protocol to monitor the occurrence of glaucoma and glaucoma suspect.

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the incidence of glaucoma after congenital cataract surgery | A Kaplan-Meier analysis was used | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors of glaucoma after congenital cataract surgery | Piecewise exponential survival models with mixed effects (PEWSMME) were used.(variables including demographic characters, surgery categories, clinical history, length of follow up). | baseline |
Observational Study Using the CoVa Monitoring System 3

Study Overview
=================
Brief Summary
-----------------
Asthma is a complex and chronic inflammatory disorder which is associated with reversible airway obstruction and bronchial hyperresponsiveness. It is one of the most prevalent chronic diseases in children and prevalence further increases worldwide. Typical symptoms of asthma are breathlessness, cough, wheezing and chest tightness. These symptoms are particularly prevalent at night-time. Understanding and tracking these symptoms can lead to better management of asthma. Auscultation using a stethoscope is standard clinical practice, however there is currently no available solution to detect respiratory sounds throughout the day and night. The aim of this study is to investigate the feasibility of detecting respiratory sounds in healthy children with the CoVa patch.

Official Title
-----------------
Observational Study to Detect Cough and Wheeze Sounds Using the CoVa Monitoring System 3

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Device: Cova Monitoring System 3


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant is between the ages of 4 - 17 years old at the time of consent Participant and/or family member/carer willing to give written consent Participant and/or family member/carer who can read and comprehend english Exclusion Criteria: Subject believed to be unsuitable for inclusion by the Principle Investigator Subject is pregnant at time of consent Subject is currently enrolled in another medical study

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HealthyVolunteers<br> | Device: Cova Monitoring System 3<br>* Healthy Volunteers<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ability to detect simulated respiratory sounds including coughing and wheezing or identify subjects which have asthma related respiratory issues | Subjects will be asked to simulate coughing and wheezing sounds. This data will be analyzed by using a phonocardiogram (microphone) sensor. | 2 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ability to detect simulated respiratory sounds including wheeze and cough during movement such a simulated situation of moving in bed. | Subjects will be asked to simulate coughing and wheezing sounds. This data will be analyzed by using a phonocardiogram (microphone) sensor while the subject is moving in the bed. | 2 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Healthy volunteers
The Critical Care Response to the COVID-19 Pandemic in Madrid

Study Overview
=================
Brief Summary
-----------------
Description of the adaptation of ICUs in the region of Madrid to que surge in demand of critical care due to COVID-19

Detailed Description
-----------------
Background The worldwide SARS-CoV-2 pandemic has put healthcare systems under the extreme pressure, with intensive care units being faced with a previously unseen number of patients with severe respiratory failure requiring admission for endotracheal intubation and mechanical ventilation. Methods The study describes how the critical care resources adapted to the sudden surge of severe Covid-19 in the province of Madrid, which developed at the beginning of March 2020. The response consisted of a swift increase in ICU capacity and the relocation of patients. ICU beds were mounted outside the usual intensive care areas. Transfer of critically ill intubated patients with COVID-19 was managed in an instant messenger service group composed of representatives of 53 intensive care units and performed by the Madrid Emergency Medical Systems (EMS). The investigators will compare transferred with non-transferred patients matched for risk factors for cardiovascular and respiratory complications.

Official Title
-----------------
The Critical Care Resources Adaptation to the SARS-CoV-2 Pandemic in Madrid

Conditions
-----------------
COVID-19, ARDS, Human

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted to ICU in Madrid with COVID-19 Exclusion Criteria: Admitted to ICU without COVID-19
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Transferred patients<br>A subgroup of Critically ill intubated patients with COVID-19 associated ARDS were transferred from overwhelmed ICUs to other with available free beds | |
| Matched Non-transferred patients<br>A subgroup from the global cohort, matched for risk factors will be compared with transferred patients for outcome variables | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | ICU mortality | 9 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of ICU stay | From admission to discharge or death | 9 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, ARDS, Relocation, ICU capacity